Skip to main content

Advertisement

SpringerLink
Log in

The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies

  • How I Manage
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

The gastrointestinal tract is heavily populated with innate and adaptive immune cells that have an active role in preservation of mucosal homeostasis and prevention of inflammation. Inflammatory bowel diseases are thought to result from dysregulated immune function that is influenced by genetic background, environmental triggers, and microbiome changes. While most inflammatory bowel disease patients present in adolescent years or adulthood, in a minority of cases, the disease develops early in life, and in some of these young patients, a monogenic disease causing intestinal inflammation can be identified. Many of these conditions result from mutations in immune-mediated genes and can present with or without concomitant recurrent infections. In this review, we will discuss the treatment of patients with selected primary immunodeficiencies and inflammatory bowel diseases. We will focus on five conditions resulting from mutations in IL10/IL10 receptor, NADPH oxidase complex, XIAP, LRBA, and CTLA-4.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298–306.

    Article  PubMed  CAS  Google Scholar 

  4. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.

    Article  PubMed  Google Scholar 

  5. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–19.

    Article  PubMed  Google Scholar 

  6. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:1–20.

    Article  Google Scholar 

  7. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology. 2012;143:285–8.

    Article  PubMed  Google Scholar 

  9. Kammermeier J, Dziubak R, Pescarin M, et al. Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years. J Crohns Colitis. 2017;11(1):60–69.

  10. Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr. 2006;43:603–9.

    Article  PubMed  Google Scholar 

  11. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.

    Article  PubMed  Google Scholar 

  12. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ. Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr. 2005;40:582–8.

    Article  PubMed  Google Scholar 

  13. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62:1795–805.

    Article  PubMed  CAS  Google Scholar 

  15. Kelsen JR, Baldassano RN, Artis D, Sonnenberg GF. Maintaining intestinal health: the genetics and immunology of very early onset inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2015;1:462–76.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Uhlig HH, Schwerd T. From genes to mechanisms: the expanding spectrum of monogenic disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:202–12.

    Article  PubMed  Google Scholar 

  17. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, et al. Variants in TRIM22 that affect NOD2 signaling are associated with very-early-onset inflammatory bowel disease. Gastroenterology. 2016;150:1196–207.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27:89–99. viii

    Article  PubMed  Google Scholar 

  20. Dupuis-Girod S, Medioni J, Haddad E, Quartier P, Cavazzana-Calvo M, le Deist F, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:e622–7.

    Article  PubMed  Google Scholar 

  21. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51:1429–34.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347–55.

    Article  PubMed  CAS  Google Scholar 

  23. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349:436–40.

    Article  PubMed  CAS  Google Scholar 

  24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.

    Article  PubMed  CAS  Google Scholar 

  25. Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177–210.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med. 1998;187:571–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263–74.

    Article  PubMed  CAS  Google Scholar 

  28. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10:1178–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Kamanaka M, Huber S, Zenewicz LA, Gagliani N, Rathinam C, O'Connor W Jr, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011;208:1027–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Huber S, Gagliani N, Esplugues E, O'Connor W Jr, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34:554–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34:566–78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40:706–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Zigmond E, Bernshtein B, Friedlander G, Walker CR, Yona S, Kim KW, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014;40:720–33.

    Article  PubMed  CAS  Google Scholar 

  34. Li B, Gurung P, Malireddi RK, et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nat Commun. 2015;6:6131.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Li B, Alli R, Vogel P, Geiger TL. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis. Mucosal Immunol. 2014;7:869–78.

    Article  PubMed  CAS  Google Scholar 

  36. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, et al. Infant colitis—it’s in the genes. Lancet. 2010;376:1272.

    Article  PubMed  Google Scholar 

  37. Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013;19:2820–8.

    Article  PubMed  Google Scholar 

  38. Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011;106:1544–55.

    Article  PubMed  CAS  Google Scholar 

  39. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131:825–30.

    Article  PubMed  CAS  Google Scholar 

  40. Huang Z, Peng K, Li X, Zhao R, You J, Cheng X, et al. Mutations in interleukin-10 receptor and clinical phenotypes in patients with very early onset inflammatory bowel disease: a Chinese VEO-IBD Collaboration Group Survey. Inflamm Bowel Dis. 2017;23:578–90.

    Article  PubMed  Google Scholar 

  41. Murugan D, Albert MH, Langemeier J, Bohne J, Puchalka J, Järvinen PM, et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J Clin Immunol. 2014;34:331–9.

    Article  PubMed  CAS  Google Scholar 

  42. Kominsky DJ, Campbell EL, Ehrentraut SF, Wilson KE, Kelly CJ, Glover LE, et al. IFN-gamma-mediated induction of an apical IL-10 receptor on polarized intestinal epithelia. J Immunol. 2014;192:1267–76.

    Article  PubMed  CAS  Google Scholar 

  43. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS. Ligation of intestinal epithelial CD1d induces bioactive IL-10: critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci U S A. 1999;96:13938–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Quiros M, Nishio H, Neumann PA, Siuda D, Brazil JC, Azcutia V, et al. Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. J Clin Invest. 2017;127:3510–20.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Zheng L, Kelly CJ, Battista KD, Schaefer R, Lanis JM, Alexeev EE, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol. 2017;199:2976–84.

    Article  PubMed  CAS  Google Scholar 

  46. Lanis JM, Alexeev EE, Curtis VF, Kitzenberg DA, Kao DJ, Battista KD, et al. Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia. Mucosal Immunol. 2017;10:1133–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood. 2013;122:3713–22.

    Article  PubMed  CAS  Google Scholar 

  48. Shouval DS, Ebens CL, Murchie R, et al. Large B-cell lymphoma in an adolescent patient with IL-10 receptor deficiency and history of infantile inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;63(1):e15–7.

  49. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell. 2011;20:781–96.

    Article  PubMed  CAS  Google Scholar 

  50. Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, et al. Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology. 2016;151:1100–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513–9.

    Article  PubMed  CAS  Google Scholar 

  52. Shouval DS, Konnikova L, Griffith AE, et al. Enhanced TH17 responses in patients with IL10 receptor deficiency and infantile-onset IBD. Inflamm Bowel Dis. 2017;23:1950–61.

    Article  PubMed  Google Scholar 

  53. Schappi MG, Klein NJ, Lindley KJ, et al. The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr. 2003;36:623–31.

    Article  PubMed  Google Scholar 

  54. Schappi MG, Smith VV, Goldblatt D, et al. Colitis in chronic granulomatous disease. Arch Dis Child. 2001;84:147–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O'Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114:462–8.

    Article  PubMed  Google Scholar 

  56. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am J Gastroenterol. 2009;104:117–24.

    Article  PubMed  CAS  Google Scholar 

  57. Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr. 2009;168:149–55.

    Article  PubMed  CAS  Google Scholar 

  58. Kawai T, Arai K, Harayama S, Nakazawa Y, Goto F, Maekawa T, et al. Severe and rapid progression in very early-onset chronic granulomatous disease-associated colitis. J Clin Immunol. 2015;35:583–8.

    Article  PubMed  Google Scholar 

  59. Khangura SK, Kamal N, Ho N, Quezado M, Zhao X, Marciano B, et al. Gastrointestinal features of chronic granulomatous disease found during endoscopy. Clin Gastroenterol Hepatol. 2016;14:395–402.e5.

    Article  PubMed  Google Scholar 

  60. Rosenbaum BE, Shenoy R, Vuppula S, Thomas K, Moy L, Kaul A. Colitis as the sole initial presentation of chronic granulomatous disease: histopathologic clues to diagnosis. Pediatr Infect Dis J. 2016;35:1229–31.

    Article  PubMed  Google Scholar 

  61. Broides A, Sagi O, Pinsk V, et al. Subclinical intestinal inflammation in chronic granulomatous disease patients. Immunol Res. 2016;64(1):155–9.

  62. Yu JE, De Ravin SS, Uzel G, et al. High levels of Crohn’s disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol. 2011;138:14–22.

    Article  PubMed  CAS  Google Scholar 

  63. Deffert C, Olleros ML, Huiping Y, Herrmann FR, Zekry D, Garcia I, et al. TNF-alpha blockade in chronic granulomatous disease-induced hyperinflammation: patient analysis and murine model. J Allergy Clin Immunol. 2011;128:675–7.

    Article  PubMed  CAS  Google Scholar 

  64. Kawai T, Watanabe N, Yokoyama M, Arai K, Oana S, Harayama S, et al. Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. Clin Immunol. 2013;147:122–8.

    Article  PubMed  CAS  Google Scholar 

  65. Noel N, Mahlaoui N, Blanche S, Suarez F, Coignard-Biehler H, Durieu I, et al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol. 2013;132(4):997–1000 e1.

    Article  PubMed  CAS  Google Scholar 

  66. Simon M, Pariente B, Lambert J, Cosnes J, Bouhnik Y, Marteau P, et al. Long-term outcomes of thalidomide therapy for adults with refractory Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14:966–972.e2.

    Article  PubMed  CAS  Google Scholar 

  67. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A. 2014;111:3526–31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Hahn KJ, Ho N, Yockey L, Kreuzberg S, Daub J, Rump A, et al. Treatment with anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis. Am J Gastroenterol. 2015;110:938–9.

    Article  PubMed  CAS  Google Scholar 

  69. Butte MJ, Park KT, Lewis DB. Treatment of CGD-associated colitis with the IL-23 blocker ustekinumab. J Clin Immunol. 2016;36:619–20.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Kang EM, Marciano BE, DeRavin S, Zarember KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2011;127:1319–26. quiz 1327–8

    Article  PubMed  PubMed Central  Google Scholar 

  71. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344:881–8.

    Article  PubMed  CAS  Google Scholar 

  72. Parta M, Kelly C, Kwatemaa N, Theobald N, Hilligoss D, Qin J, et al. Allogeneic reduced-intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective trial. J Clin Immunol. 2017;37:548–58.

    Article  PubMed  CAS  Google Scholar 

  73. Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436–48.

    Article  PubMed  CAS  Google Scholar 

  74. Kato K, Kojima Y, Kobayashi C, Mitsui K, Nakajima-Yamaguchi R, Kudo K, et al. Successful allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease with inflammatory complications and severe infection. Int J Hematol. 2011;94:479–82.

    Article  PubMed  Google Scholar 

  75. Gungor T, Halter J, Klink A, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation. 2005;79:1596–606.

    Article  PubMed  Google Scholar 

  76. Hauck F, Koletzko S, Walz C, et al. Diagnostic and treatment options for severe IBD in female X-CGD carriers with non-random X-inactivation. J Crohns Colitis. 2016;10(1):112–5.

  77. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013;525:174–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. De Ravin SS, Li L, Wu X, et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. Sci Transl Med. 2017;9:eaah3480.

    Article  PubMed  CAS  Google Scholar 

  79. Muise AM, Xu W, Guo CH, Walters TD, Wolters VM, Fattouh R, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012;61:1028–35.

    Article  PubMed  CAS  Google Scholar 

  80. Dhillon SS, Fattouh R, Elkadri A, Xu W, Murchie R, Walters T, et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology. 2014;147:680–689.e2.

    Article  PubMed  CAS  Google Scholar 

  81. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110–4.

    Article  PubMed  CAS  Google Scholar 

  82. Aguilar C, Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. J Clin Immunol. 2015;35:331–8.

    Article  PubMed  CAS  Google Scholar 

  83. Schwerd T, Pandey S, Yang HT, et al. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn’s disease. Gut. 2017;66(6):1060–1073.

  84. Girardelli M, Arrigo S, Barabino A, Loganes C, Morreale G, Crovella S, et al. The diagnostic challenge of very early-onset enterocolitis in an infant with XIAP deficiency. BMC Pediatr. 2015;15:208.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117:1522–9.

    Article  PubMed  CAS  Google Scholar 

  86. Aguilar C, Lenoir C, Lambert N, Bègue B, Brousse N, Canioni D, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol. 2014;134:1131–1141.e9.

    Article  PubMed  CAS  Google Scholar 

  87. Dziadzio M, Ammann S, Canning C, Boyle F, Hassan A, Cale C, et al. Symptomatic males and female carriers in a large Caucasian kindred with XIAP deficiency. J Clin Immunol. 2015;35:439–44.

    Article  PubMed  CAS  Google Scholar 

  88. Yang X, Kanegane H, Nishida N, Imamura T, Hamamoto K, Miyashita R, et al. Clinical and genetic characteristics of XIAP deficiency in Japan. J Clin Immunol. 2012;32:411–20.

    Article  PubMed  CAS  Google Scholar 

  89. Speckmann C, Lehmberg K, Albert MH, Damgaard RB, Fritsch M, Gyrd-Hansen M, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol. 2013;149:133–41.

    Article  PubMed  CAS  Google Scholar 

  90. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011;13:255–62.

    Article  PubMed  Google Scholar 

  91. Zeissig Y, Petersen BS, Milutinovic S, et al. XIAP variants in male Crohn's disease. Gut. 2015;64:66–76.

    Article  PubMed  CAS  Google Scholar 

  92. Kelsen JR, Dawany N, Martinez A, Grochowski CM, Maurer K, Rappaport E, et al. A de novo whole gene deletion of XIAP detected by exome sequencing analysis in very early onset inflammatory bowel disease: a case report. BMC Gastroenterol. 2015;15:160.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Tsuma Y, Imamura T, Ichise E, Sakamoto K, Ouchi K, Osone S, et al. Successful treatment of idiopathic colitis related to XIAP deficiency with allo-HSCT using reduced-intensity conditioning. Pediatr Transplant. 2015;19:E25–8.

    Article  PubMed  Google Scholar 

  94. Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013;121:877–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Worth AJ, Nikolajeva O, Chiesa R, et al. Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis. Blood. 2013;121:4966–8.

    Article  PubMed  CAS  Google Scholar 

  96. Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet. 2012;90:986–1001.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Alkhairy OK, Abolhassani H, Rezaei N, Fang M, Andersen KK, Chavoshzadeh Z, et al. Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol. 2016;36:33–45.

    Article  PubMed  CAS  Google Scholar 

  98. Gamez-Diaz L, August D, Stepensky P, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137:223–30.

    Article  PubMed  CAS  Google Scholar 

  99. Charbonnier LM, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135:217–27.

    Article  PubMed  CAS  Google Scholar 

  100. Revel-Vilk S, Fischer U, Keller B, Nabhani S, Gámez-Díaz L, Rensing-Ehl A, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol. 2015;159:84–92.

    Article  PubMed  CAS  Google Scholar 

  101. Schreiner F, Plamper M, Dueker G, Schoenberger S, Gámez-Díaz L, Grimbacher B, et al. Infancy-onset T1DM, short stature, and severe immunodysregulation in two siblings with a homozygous LRBA mutation. J Clin Endocrinol Metab. 2016;101:898–904.

    Article  PubMed  CAS  Google Scholar 

  102. Levy E, Stolzenberg MC, Bruneau J, et al. LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. Clin Immunol. 2016;168:88–93.

    Article  PubMed  CAS  Google Scholar 

  103. Kostel Bal S, Haskologlu S, Serwas NK, Islamoglu C, Aytekin C, Kendirli T, et al. Multiple presentations of LRBA deficiency: a single-center experience. J Clin Immunol. 2017;37:790–800.

    Article  PubMed  CAS  Google Scholar 

  104. Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol. 2012;130:481–488.e2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Serwas NK, Kansu A, Santos-Valente E, Kuloğlu Z, Demir A, Yaman A, et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis. 2015;21:40–7.

    Article  PubMed  Google Scholar 

  106. Azizi G, Abolhassani H, Mahdaviani SA, Chavoshzadeh Z, Eshghi P, Yazdani R, et al. Clinical, immunologic, molecular analyses and outcomes of Iranian patients with LRBA deficiency: a longitudinal study. Pediatr Allergy Immunol. 2017;28:478–84.

    Article  PubMed  Google Scholar 

  107. Azizi G, Abolhassani H, Yazdani R, Mohammadikhajehdehi S, Parvaneh N, Negahdari B, et al. New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency. Eur Ann Allergy Clin Immunol. 2017;49:235–9.

    Article  PubMed  CAS  Google Scholar 

  108. Tesi B, Priftakis P, Lindgren F, Chiang SCC, Kartalis N, Löfstedt A, et al. Successful hematopoietic stem cell transplantation in a patient with LPS-responsive beige-like anchor (LRBA) gene mutation. J Clin Immunol. 2016;36:480–9.

    Article  PubMed  CAS  Google Scholar 

  109. Seidel MG, Hirschmugl T, Gamez-Diaz L, Schwinger W, Serwas N, Deutschmann A, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol. 2015;135:1384–1390.e8.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Seidel MG, Bohm K, Dogu F, et al. Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2018;141(2):770–775.

  111. Bakhtiar S, Gamez-Diaz L, Jarisch A, et al. Treatment of infantile inflammatory bowel disease and autoimmunity by allogeneic stem cell transplantation in LPS-responsive beige-like anchor deficiency. Front Immunol. 2017;8:52.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Krummey SM, Ford ML. Braking bad: novel mechanisms of CTLA-4 inhibition of T cell responses. Am J Transplant. 2014;14:2685–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 2011;32:428–33.

    Article  PubMed  CAS  Google Scholar 

  114. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105–11.

    Article  PubMed  CAS  Google Scholar 

  115. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7.

    Article  PubMed  CAS  Google Scholar 

  116. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.

    Article  PubMed  CAS  Google Scholar 

  117. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015;64:1889–97.

    Article  PubMed  CAS  Google Scholar 

  120. Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J Allergy Clin Immunol. 2018;S0091-6749(18):30630–4.

  121. Hayakawa S, Okada S, Tsumura M, Sakata S, Ueno Y, Imai K, et al. A patient with CTLA-4 haploinsufficiency presenting gastric cancer. J Clin Immunol. 2016;36:28–32.

    Article  PubMed  CAS  Google Scholar 

  122. Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, et al. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol. 2017;139:1043–1046.e5.

    Article  PubMed  CAS  Google Scholar 

  123. Slatter MA, Engelhardt KR, Burroughs LM, Arkwright PD, Nademi Z, Skoda-Smith S, et al. Hematopoietic stem cell transplantation for CTLA4 deficiency. J Allergy Clin Immunol. 2016;138:615–619.e1.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Jeff Goldsmith for his assistance in obtaining histological images of the patients.

Funding

D.S.S. is supported by the Israel Science Foundation, the Israel-US Binational Science Foundation, and Jeffery Modell Foundation grants. M.K. is supported by a NIH T32 grant (DK007477-34). S.B.S. is supported by NIH grants HL59561, DK034854, and AI50950; the Helmsley Charitable Trust; and the Wolpow Family Chair in IBD Treatment and Research.

Author information

Authors and Affiliations

  1. Pediatric Gastroenterology Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    Dror S. Shouval

  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Dror S. Shouval

  3. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA, USA

    Dror S. Shouval, Matthew Kowalik & Scott B. Snapper

  4. VEO-IBD International Consortium, Boston, USA

    Dror S. Shouval, Matthew Kowalik & Scott B. Snapper

  5. Harvard Medical School, Boston, MA, USA

    Matthew Kowalik & Scott B. Snapper

  6. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA, USA

    Scott B. Snapper

Authors
  1. Dror S. Shouval
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Kowalik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott B. Snapper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott B. Snapper.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shouval, D.S., Kowalik, M. & Snapper, S.B. The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies. J Clin Immunol 38, 579–588 (2018). https://doi.org/10.1007/s10875-018-0524-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-018-0524-9

Keywords

Search

Navigation